Licensing as a Commercialisation Strategy for German Biotechnology Firms
Due to a lack of resources in new high-tech firms market access is quite diffcult. Furthermore, they do not have a reputation in the market for reliable products. Contractual arrangements with more established firms, such as licensing agreements, are one way for new firms to profit from technological innovation. The aim of this study is to investigate how country differences between German and American biotechnology firms affect the usage of licensing as a commercialisation strategy.
To our knowledge, this item is not available for
download. To find whether it is available, there are three
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
|Date of creation:||30 Jan 2007|
|Publication status:||Published as "Licensing as a Commercialisation Strategy for Biotechnology Firms", in: Chen, J., Xu, Q., Wu, X. (Eds.): Managing Total Innovation and Open Innovation in the 21st Century, 2007, Zhejiang University Press: Hangzhou, S.1149-1152.|
|Contact details of provider:|| Postal: Carl-Zeiss-Strasse 3, 07743 JENA|
Phone: +049 3641/ 9 43000
Fax: +049 3641/ 9 43000
Web page: http://www.wiwi.uni-jena.de/
More information through EDIRC
|Order Information:|| Postal: If a paper is not downloadable, please contact the author(s) or the library of University of Jena, not the archive maintainer.|
When requesting a correction, please mention this item's handle: RePEc:jen:jenjbe:2007-01. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ()
If references are entirely missing, you can add them using this form.